Economic impact of severe and non-severe hypoglycemia in patients with Type 1 and Type 2 diabetes in the United States

References

• American Diabetes Association. Standards of medical care in diabetes 2011. Diabetes Care 2011;34(1 Suppl):11–61
   Google Scholar
• Cryer PE. Hypoglycemia: still the limiting factor in the glycemic management of diabetes. Endocr Pract 2008;14:750–6
   PubMedGoogle Scholar
• Marrett E, Radican L, Davies MJ, et al. Assessment of severity and frequency of self-reported hypoglycemia on quality of life in patients with type 2 diabetes treated with oral antihyperglycemic agents: a survey study. BMC Res Notes 2011;4:251
   PubMedGoogle Scholar
• ACCORD Study Group, Gerstein HC, Miller ME, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011;364:818–28
   PubMed Web of Science ®Google Scholar
• UK Hypoglycaemia Study Group. Risk of hypoglycemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 2007;50:1140–7
   PubMed Web of Science ®Google Scholar
• Brod M, Christensen T, Thomsen TL, et al. The impact of non-severe hypoglycemic events on work productivity and diabetes management. Value Health 2011;14:665–71
   PubMed Web of Science ®Google Scholar
• Tahrani A, Barnett AH, Brod M, et al. Global survey finds three quarters of patients experience hypoglycemia on insulin analogue causing dose irregularities and increased blood-glucose monitoring. Poster number 222 presented at: 48th EASD Annual Meeting; October 1-5, 2012; Berlin, Germany
   Google Scholar
• Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004;20(1 Suppl):5–26
   PubMed Web of Science ®Google Scholar
• McEwan P, Foos V, Palmer JL, et al. Validation of the IMS CORE Diabetes Model. Value Health 2014;17:714–24
   PubMed Web of Science ®Google Scholar
• Jönsson L, Bolinder B, Lundkvist J. Cost of hypoglycemia in patients with type 2 diabetes in Sweden. Value Health 2006;9:193–8
   PubMed Web of Science ®Google Scholar
• Cobden D, Lee WC, Balu S, et al. Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus. Pharmacotherapy 2007;27:948–62
   PubMed Web of Science ®Google Scholar
• Bullano MF, Fisher MD, Grochulski WD, et al. Hypoglycemic events and glycosylated hemoglobin values in patients with type 2 diabetes mellitus newly initiated on insulin glargine or premixed insulin combination products. Am J Health Syst Pharm 2006;63:2473–82
   PubMed Web of Science ®Google Scholar
• Leese GP, Wang J, Broomhall J, et al. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care 2003;26:1176–80
   PubMed Web of Science ®Google Scholar
• Curkendall SM, Zhang B, Oh KS, et al. Incidence and cost of hypoglycemia among patients with type 2 diabetes in the United States: analysis of a health insurance database. J Clin Outcome Manag 2011;18:455–62
   Google Scholar
• Lee WC, Balu S, Cobden D, et al. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clin Ther 2006;28:1712–25
   PubMed Web of Science ®Google Scholar
• Fabunmi R, Nielsen LL, Quimbo R, et al. Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine. Curr Med Res Opin 2009;25:777–86
   PubMed Web of Science ®Google Scholar
• Lundkvist J, Berne C, Bolinder B, et al. The economic and quality of life impact of hypoglycemia. Eur J Health Econ 2005;6:197–202
   PubMedGoogle Scholar
• Quilliam BJ, Simeone JC, Ozbay AB, et al. The incidence and costs of hypoglycemia in type 2 diabetes. Am J Manag Care 2011;17:673–80
   PubMed Web of Science ®Google Scholar
• Williams SA, Pollack MF, Dibonaventura M. Effects of hypoglycemia on health-related quality of life, treatment satisfaction and healthcare resource utilization in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2011;91:363–70
   PubMed Web of Science ®Google Scholar
• Hammer M, Lammert M, Mejías SM, et al. Costs of managing severe hypoglycaemia in three European countries. J Med Econ 2009;12:281–90
   PubMedGoogle Scholar
• Davis RE, Morrissey M, Peters JR, et al. Impact of hypoglycemia on quality of life and productivity in type 1 and type 2 diabetes. Curr Med Res Opin 2005;21:1477–83
   PubMed Web of Science ®Google Scholar
• Gold AE, MacLeod KM, Frier BM. Frequency of severe hypoglycemia in patients with type 1 diabetes with impaired awareness of hypoglycemia. Diabetes Care 1994;17:697–703
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193–203
   PubMed Web of Science ®Google Scholar
• Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and The Endocrine Society. Diabetes Care 2013;36:1384–95
   PubMed Web of Science ®Google Scholar
• U.S. Department of Labor. Bureau of Labor Statistics. U.S. consumer price index—all urban consumers. Medical care 1982-84. http://data.bls.gov/cgi-bin/surveymost?cu. Accessed August 2014
   Google Scholar
• Hay JW, Smeeding J, Carroll NV, et al. Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: The ISPOR Drug Cost Task Force Report-Part I. Value Health 2010;13:3–7
   PubMed Web of Science ®Google Scholar
• US Bureau of Labor Statistics. http://www.bls.gov. Accessed June 15, 2013
   Google Scholar
• Werner CA. U.S. Department of Commerce, Economics and Statistics Administration U.S. Census Bureau. The Older Population: 2010. 2011. http://www.census.gov/prod/cen2010/briefs/c2010br-09.pdf. Accessed September 17, 2014
   Google Scholar
• Howden LM. U.S. Department of Commerce, Economics and Statistics Administration, U.S. Census Bureau. Age and Sex Composition: 2010, 2010 Census Briefs. 2011. http://www.census.gov/prod/cen2010/briefs/c2010br-03.pdf. Accessed September 17, 2014
   Google Scholar
• U.S. Census Bureau. State & county quick facts. http://quickfacts.census.gov/qfd/states/00000.html. Accessed September 17, 2014
   Google Scholar
• WorldatWork. Paid time off programs and practices: a survey of WorldatWork members, May 2010. http://www.worldatwork.org/waw/adimLink?id=38913. Accessed September 17, 2014
   Google Scholar
• Leiter LA, Yale JF, Chiasson JL, et al. Assessment of the impact of fear of hypoglycemic episodes on glycemic and hypoglycemia management. Can J Diabetes 2005;29:186–92
   Google Scholar
• Currie CJ, Morgan CL, Poole CD, et al. Multivariate models of health-related utility and the fear of hypoglycemia in people with diabetes. Curr Med Res Opin 2006;22:1523–34
   PubMed Web of Science ®Google Scholar
• Yeaw J, Lee WC, Aagren M, et al. Cost of self-monitoring of blood glucose in the United States among patients on an insulin regimen for diabetes. J Manag Care Pharm 2012;18:21–32
   PubMed Web of Science ®Google Scholar
• Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes 2008;57:3169–76
   PubMed Web of Science ®Google Scholar
• Saleh M, Grunberger G. Hypoglycemia: an excuse for poor glycemic control? Clin Diabetes 2001;19:161–7
   Google Scholar
• Heaton A, Martin S, Brelje T. The economic effect of hypoglycemia in a health plan. Manag Care Interface 2003;16:23–7
   PubMedGoogle Scholar